urtica dioica treatment benign prostatic hyperplasia prospective randomized double-blind placebo-controlled crossover study pubmed ncbi abstract purpose determine effects therapy urtica dioica symptomatic relief lower urinary tract symptoms luts secondary benign prostatic hyperplasia bph material methods num month double-blind placebo-controlled randomized partial crossover comparative trial urtica dioica placebo num patients conducted patients evaluated international prostate symptom score ipss maximum urinary flow rate qmax postvoid residual urine volume pvr serum prostatic specific antigen psa testosterone levels prostate size end num month trial unblinding revealed patients initially received placebo switched urtica dioica groups continued medication num months results num patients num completed study num num urtica dioica group num num placebo group intention to-treat analysis end num month trial num num patients urtica dioica group reported improved luts compared num num patients placebo group num ipss qmax showed greater improvement drug placebo ipss num num urtica dioica num num placebo num peak flow rates improved num ml/s placebo recipients num ml/s treated patients num urtica dioica group pvr decreased initial num num ml num appreciable change placebo group serum psa testosterone levels unchanged groups modest decrease prostate size measured transrectal ultrasonography trus urtica dioica group num cc initially num cc num change prostate volume end study placebo num month follow-up patients continued therapy favorable treatment variables side effects identified group conclusion present study urtica dioica beneficial effects treatment symptomatic bph clinical trials conducted confirm results concluding urtica dioica effective 
